KOL Perspectives: Rituximab Use in Lupus
This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.
(EMAILWIRE.COM, December 06, 2018 ) Key Highlights
- Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price
- Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results
- Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.
Get More Information about this report at http://www.orbisresearch.com/contacts/request-sample/2392056
Questions topics -
- Current & future use of RTX in lupus
- Views on RTXs Phase II/III EXPLORER trial re-analysis
- Opinion on data demonstrating that RTX is effective for the management of refractory SLE
- Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy
- Lupus patients most suitable for RTX + BEL combination therapy
- Use of RTX + BEL combination therapy
Scope
- The insight briefing is based on Sociable Pharmas analysis of primary research with our Lupus key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during Q2 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Companies Mentioned:
Roche
GSK
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392056
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
- Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price
- Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results
- Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.
Get More Information about this report at http://www.orbisresearch.com/contacts/request-sample/2392056
Questions topics -
- Current & future use of RTX in lupus
- Views on RTXs Phase II/III EXPLORER trial re-analysis
- Opinion on data demonstrating that RTX is effective for the management of refractory SLE
- Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy
- Lupus patients most suitable for RTX + BEL combination therapy
- Use of RTX + BEL combination therapy
Scope
- The insight briefing is based on Sociable Pharmas analysis of primary research with our Lupus key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during Q2 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Companies Mentioned:
Roche
GSK
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392056
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results